drugset
drugset / Trial / NCT05256732

Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal

NCT05256732 ↗

Phase 1 Completed 136 enrolled Atea Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 following oral administration under fasting conditions or with a meal in healthy adult subjects

Timeline

Start
2022-02-22
Primary completion
2022-08-23
Completion
2022-08-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemnifosbuvir Other / unclassified — Oral

Indications

No indication recorded.